Translational Session

APOL1: The Dawning of the Era of Treatment

November 10, 2019 | 10:00 AM - 12:00 PM

Location: 150, Walter E. Washington Convention Center

Session Description

This session reviews the expanding spectrum of APOL1-associated disease, mechanisms whereby APOL1 kidney-risk variants may produce cellular dysfunction, the targeting of modifying factors and potential for antisense oligonucleotide (ASO) therapy to prevent formation of APOL1 kidney-risk variant proteins, and the application of genomics and precision medicine in ESKD.

Learning Objective(s)

  • Discuss the spectrum of APOL1-associated disease
  • Describe the mechanisms whereby APOL1 renal-risk variant proteins cause renal cell death
  • Present the evidence for ASO therapy in the treatment of inherited disease
  • Discuss the use of genetic data in personalized medicine in patients with CKD

Learning Pathway(s)

  • Chronic Kidney Disease
  • Genetic Diseases of the Kidneys


  • Barry I. Freedman, MD
  • Ebele M. Umeukeje, MD, MPH

Patient Voice/Commentator

  • Patrick O. Gee, PhD